Literature DB >> 10445964

Assessing frontal lobe behavioral syndromes with the frontal lobe personality scale.

J Grace1, J C Stout, P F Malloy.   

Abstract

Reliability and construct validity are reported for the Frontal Lobe Personality Scale (FLOPS), a brief neurobehavior rating scale. The FLOPS Family form was completed by family members of 24 frontal lobe brain-damaged patients, 15 non-frontal lobe brain- damaged patients, and 48 healthy controls. Intrascale reliability was demonstrated (internal consistency.96; split half.93). Validity studies of frontal lobe patients post-lesion compared to their pre-lesion status, to healthy controls, and of frontal lobe patients pre- and post-lesion compared to non-frontal lobe patients pre- and post-lesion, indicated that frontal lobe patients post-lesion showed significantly more frontal behavior than (a) pre-lesion frontal lobe patients, (b) healthy controls, and (c) post-lesion non-frontal lobe patients. The FLOPS appears to be useful for quantifying frontal lobe behavior in clinical and research settings.

Entities:  

Mesh:

Year:  1999        PMID: 10445964     DOI: 10.1177/107319119900600307

Source DB:  PubMed          Journal:  Assessment        ISSN: 1073-1911


  47 in total

Review 1.  Personality in frontal lobe disorders.

Authors:  T W Chow
Journal:  Curr Psychiatry Rep       Date:  2000-10       Impact factor: 5.285

2.  A study of persistent post-concussion symptoms in mild head trauma using positron emission tomography.

Authors:  S H A Chen; D A Kareken; P S Fastenau; L E Trexler; G D Hutchins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

Review 3.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

Review 4.  Are the available apathy measures reliable and valid? A review of the psychometric evidence.

Authors:  Diana E Clarke; Jean Y Ko; Emily A Kuhl; Robert van Reekum; Rocio Salvador; Robert S Marin
Journal:  J Psychosom Res       Date:  2010-03-31       Impact factor: 3.006

5.  Widespread microstructural white matter involvement in amyotrophic lateral sclerosis: a whole-brain DTI study.

Authors:  M Cirillo; F Esposito; G Tedeschi; G Caiazzo; A Sagnelli; G Piccirillo; R Conforti; F Tortora; M R Monsurrò; S Cirillo; F Trojsi
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-02       Impact factor: 3.825

6.  Frontal systems deficits in stimulant-dependent patients: evidence of pre-illness dysfunction and relationship to treatment response.

Authors:  Theresa M Winhusen; Eugene C Somoza; Daniel F Lewis; Frankie B Kropp; Viviana Elizabeth Horigian; Bryon Adinoff
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

7.  Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances.

Authors:  Caitlin N Pope; Jessica L Montoya; Elizabeth Vasquez; Josué Pérez-Santiago; Ronald Ellis; J Allen McCutchan; Dilip V Jeste; David J Moore; María J Marquine
Journal:  J Neurovirol       Date:  2020-07-30       Impact factor: 2.643

8.  Validity of the Verbal Concept Attainment Test in multiple sclerosis.

Authors:  Ryan Mulligan; Michael R Basso; Lily Lau; Bradley Reynolds; Douglas M Whiteside; Dennis Combs; Robert A Bornstein
Journal:  J Clin Exp Neuropsychol       Date:  2019-01-14       Impact factor: 2.475

9.  An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial.

Authors:  Nancy D Chiaravalloti; Nancy B Moore; Olga M Nikelshpur; John DeLuca
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

Review 10.  Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures.

Authors:  Laura N Gitlin; Katherine A Marx; Ian H Stanley; Bryan R Hansen; Kimberly S Van Haitsma
Journal:  Int Psychogeriatr       Date:  2014-08-06       Impact factor: 3.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.